Knight Therapeutics Inc. reconfirmed earnings guidance for the year 2024. Knight expects to generate between $335 million to $350 million in revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 CAD | -0.67% | -2.93% | +14.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 441M | |
+8.29% | 8.79B | |
-15.14% | 4.88B | |
+50.73% | 4.73B | |
+4.36% | 3.92B | |
-26.13% | 2.2B | |
+12.07% | 2.28B | |
+16.45% | 2.11B | |
-33.59% | 2.08B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024